Clinical Trials Browser

INDUSTRY × Recurrence × belinostat × Clear all

NCT02679131 2019-11-20

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Phase 1 Terminated

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms, Renal Insufficiency